Lancet Psychiatry cohort tracks GLP-1 starts in 70,257 schizophrenia patients
US electronic health record study compared GLP-1 receptor agonist initiators with DPP-4, SGLT2 initiators and non-initiators for psychiatric hospitalisation and emergency presentations.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 15 07:00 ETSource: The lancet. Psychiatry
The wire
- 01Using the NeuroBlu repository, researchers followed 70,257 adults with schizophrenia and type 2 diabetes from 2018; 9,093 (12.9%) started a GLP-1 receptor agonist, with up to two years of follow-up.
- 02Prescribers managing antipsychotic-related metabolic burden have had little evidence on whether incretin therapy affects psychiatric outcomes alongside weight and glycaemia.
- 03Findings are observational and drawn from electronic records with inverse probability weighting; residual confounding and intention-to-treat exposure definitions limit causal interpretation.
From the source
Read at pubmed.ncbi.nlm.nih.govGLP-1 receptor agonist initiation and risk of psychiatric hospitalisation and emergency department presentation in adults with schizophrenia and type 2 diabetes in the USA: an observational cohort study using electronic health records data
The lancet. Psychiatry · 2026 Nov · Davoodian N, Williams LJ, Berk M et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42874603/
